At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Brief Dose Escalation Followed by a Phase 2 Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Everolimus and Trastuzumab for Breast Cancer. Completed, enrolled 11 participants across 2 sites.
Detailed Summary
The purpose of this research study is to determine the safety of RAD001 and the highest dose of this drug that can be given to people with HER2-positive metastatic breast cancer safely in combination with trastuzumab. RAD001 has been used in patients with severe rheumatoid arthritis, in recipients of solid-organ transplants, healthy volunteers and experiments with animals, and information from those other research studies suggest that this RAD001 may help to stop cancer cells from growing abnormally.
Study Details
Timeline
Interventions
Everolimus is being administered orally 7 days per week.
Trastuzumab is being administered at a dose of 6 mg/kg intravenously once every 21 days.